The primary aim of the study is to determine the proportion of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust in whom drug concentration targets are achieved.
Under follow-up for management of infection at Imperial College NHS Trust
Received a beta-lactam antibiotic within the last 48 hours (or are planned to start imminently).
Delirium which may be caused or exacerbated by having an infection.
Suspected/confirmed central nervous system infection.
Less than 18 years of age
Severe anaemia (Hb < 70g/l)
Platelets < 50x10^9/l, INR >1.5 or other known blood clotting impairment
Patient with terminal diagnosis receiving palliative care input who may experience distress if approached for this study.
As per inclusion criteria
Other
Prospective
Not listed
Determine the number of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust in whom drug concentration targets are achieved.
Determine the number of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust in whom drug concentration targets are achieved
Find the number of individuals receiving co-administered non-beta-lactam antibiotics in whom drug concentration targets are achieved.
Find the number of individuals receiving co-administered non-beta-lactam antibiotics in whom drug concentration targets are achieved.
Show how clinical co-variates, co-administered medications and treatment outcomes relate to target attainment, and identify groups of patients in who therapeutic drug monitoring may be beneficial.
Show how clinical co-variates, co-administered medications and treatment outcomes relate to target attainment, and identify groups of patients in who therapeutic drug monitoring may be beneficial.
Illustrate dynamic patterns of infection-related biomarkers which may indicate the presence/absence of treatment response.
Illustrate dynamic patterns of infection-related biomarkers which may indicate the presence/absence of treatment response.
Show how drug-levels obtained through minimally invasive sampling and the use of residual specimens relate to blood, and how these could be used to inform individual dose-optimisation.
Show how drug-levels obtained through minimally invasive sampling and the use of residual specimens relate to blood, and how these could be used to inform individual dose-optimisation.
Click on the lead sponsor to view all of their trials.
